Clinical Trials Browser

Anal Canal Carcinoma × Nivolumab × Clear all

NCT03233711 2026-03-18

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Phase 3 Active not recruiting

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT02314169 2025-04-29

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms